Navigation Links
SOTIO a.s. Appoints Chiltern International
Date:3/18/2013

LONDON and Wilmington, N.C., March 18, 2013 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that SOTIO a.s. has selected Chiltern International Limited to be the CRO that carries out the European part of its phase III global clinical trial entitled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S.

Under the agreement signed in December 2012, Chiltern will be responsible for providing full-service management of the VIABLE phase III clinical trial in Europe. It will be the contracting party for 126 treatment centers in 17 European countries where a total of 750 patients are expected to participate in the trial. Chiltern will also be responsible for processing the data obtained during this clinical evaluation.

Dr Jim Esinhart , CEO, Chiltern, commented, "I am very pleased that we have been selected to manage this high profile trial. I believe it underscores the strengths and expertise of our global Oncology Therapeutic Area Team. We look forward to working in close partnership with Sotio to deliver a quality outcome."

Company profileAbout Chiltern: Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,500 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.ch
'/>"/>

SOURCE Chiltern
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
2. Elsevier / MEDai Appoints Tom Zajac as New President
3. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
4. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
5. BioStorage Technologies Appoints New Member to Board of Directors
6. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
9. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
10. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
11. Veracyte Appoints Mark Spring as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 26, 2014 "Ischemic Stroke and ... provides data on the Ischemic Stroke and Cerebral ... information and data relating to the clinical trials ... full global Ischemic Stroke Research Report 2014 at: ... of the trial numbers and their recruitment status ...
(Date:7/25/2014)... from the University of Leicester has furthered our ... potential to create new materials using nanosized ,building ... in the prestigious academic journal Physical Review ... examine in rich detail the structure and internal ... acetylene molecule and a single helium atom. , ...
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... CBI is pleased to announce the full agenda for ... Access Congress, being held December 6-7, 2011 in Philadelphia, ... Specialty Care Solutions, delivers pre- and post-launch strategies, dynamic ... Anchored by conference chairman, Robert Besthof, Vice President, ...
... -- Third ocular product partnered with Sanofi approved ... plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the ... Food and Drug Administration (FDA) has approved its Investigational ... development of UshStat ® , a novel gene-based treatment ...
... TRIANGLE PARK, N.C., Oct. 17, 2011 Max Neeman ... hemophilia trials according to the Clinical Trials Registry-India (CTRI). ... India, Max Neeman can boast supporting 80% of these ... International has established a team of experts specialized in ...
Cached Biology Technology:Full Agenda Announced for CMAC 2011 - CBI'S 2nd Annual Commercialization and Market Access Congress 2Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 2Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 3Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B 4CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India 2
(Date:7/24/2014)... factors that characterize sustainable university and college programs ... physics teachers. Specifically, one or more faculty members ... combination with institutional motivation and commitment can ensure ... and Math (STEM) teacher shortages are especially acute ... for institutions seeking to increase the number of ...
(Date:7/24/2014)... The planet,s current biodiversity, the product of 3.5 billion ... in the history of life. But it may be ... of scientific literature and analysis of data published in ... that the loss and decline of animals is contributing ... the planet,s sixth mass biological extinction event. , Since ...
(Date:7/24/2014)... terroir, meaning the microbial populations found on surfaces in ... the final flavor according to research published ahead of ... . This is the first time investigators have taken ... Many sake makers inoculate with both bacteria and yeast, ... of California, Davis, but he and his colleagues investigated ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3The microbes make the sake brewery 2
... the University of Georgia, using glow-in-the-dark proteins and ... of a complex organelle in the bacterium that ... in new, precise detail the unique cell extension ... Mycoplasma pneumoniae. This structure, called a "terminal organelle," ...
... fruit flies, developmental biologists at the Kimmel Cancer Center ... a new way that genes are turned on and ... processes are at work in higher organisms, including mammals, ... understanding of a range of diseases, including childhood cancer. ...
... prevents the production of a critical blood-clotting protein. Treatments ... exist, may consist of risky blood transfusions or expensive ... be induced to begin producing these proteins, say by ... , Prof. Yair Reisner and Ph.D. student Anna Aronovich ...
Cached Biology News:UGA scientists unravel 'molecular inch-worm' structure of walking-pneumonia bacterium 2Jefferson researchers uncover new way nature turns genes on and off 2A transplant in time 2
CQCS kit for etra KR 4i , (other units)....
... The inductive drives of VARIOMAG Magnetic ... as motors, belts, or mechanical bearings, making ... In addition, the VARIOMAG inductive drive can ... water, dust or microorganisms. This is why ...
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
...
Biology Products: